Study of a Neurocognition Enhancing Agent in Patients With Schizophrenia

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

June 30, 2009

Primary Completion Date

September 30, 2011

Study Completion Date

September 30, 2011

Conditions
Schizophrenia
Interventions
DRUG

Pregnenolone

Pregnenolone 50 mg BID x 14 days, followed by Pregnenolone 300 mg per day for 14 days (200 mg qAM and 100 mg qPM), followed by Pregnenolone 500 mg per day for the remainder of the 8-week trial (300 mg qAM and 200 mg qPM)

DRUG

Placebo

Placebo 50 mg BID x 14 days, followed by Placebo 300 mg per day for 14 days (200 mg qAM and 100 mg qPM), followed by Placebo 500 mg per day for the remainder of the 8-week trial (300 mg qAM and 200 mg qPM)

Trial Locations (1)

539747

Institute of Mental Health, Singapore

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Duke University

OTHER

collaborator

National University of Singapore

OTHER

collaborator

Singapore Clinical Research Institute

OTHER

lead

National Research Foundation, Singapore

OTHER_GOV